Vaccine compositions and methods of use to treat neonatal subjects
US-2017304433-A1 · Oct 26, 2017 · US
Immediate protection against pathogens via MVA
US8961998B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8961998-B2 |
| Application number | US-201213589273-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 20, 2012 |
| Priority date | Apr 27, 2007 |
| Publication date | Feb 24, 2015 |
| Grant date | Feb 24, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention relates to methods and kits comprising poxviruses including, but not limited to modified vaccinia virus Ankara (MVA) and uses thereof to provide immediate protection against pathogens. Poxviruses including, but not limited to MVA can be delivered to a host animal just prior to or after exposure to a pathogen and provide protection against the pathogen.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for inducing a protective immune response against a replication competent poxvirus in a human, comprising administering to the human an immunogenic composition comprising a modified Vaccinia Ankara (MVA) virus within 72 hours after exposure to the replication competent poxvirus, wherein the administration of the immunogenic composition induces a protective immune response against the replication competent poxvirus in the human.…
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US8961998B2 cover?
- The invention relates to methods and kits comprising poxviruses including, but not limited to modified vaccinia virus Ankara (MVA) and uses thereof to provide immediate protection against pathogens. Poxviruses including, but not limited to MVA can be delivered to a host animal just prior to or after exposure to a pathogen and provide protection against the pathogen.
- Who is the assignee on this patent?
- Hochrein Hubertus, O'Keeffe Meredith, Bavarian Nordic As
- What technology area does this patent fall under?
- Primary CPC classification A61K39/285. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Feb 24 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).